Compare PGEN & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | AMPH |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2013 | 2005 |
| Metric | PGEN | AMPH |
|---|---|---|
| Price | $3.96 | $21.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $8.33 | ★ $29.29 |
| AVG Volume (30 Days) | ★ 5.6M | 393.8K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.03 |
| Revenue | $230,981,000.00 | ★ $719,887,000.00 |
| Revenue This Year | $1,115.92 | $7.19 |
| Revenue Next Year | $81.04 | $4.76 |
| P/E Ratio | ★ N/A | $10.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.23 | $17.03 |
| 52 Week High | $5.47 | $31.26 |
| Indicator | PGEN | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 58.51 |
| Support Level | $3.49 | $20.41 |
| Resistance Level | $4.44 | $22.90 |
| Average True Range (ATR) | 0.31 | 0.75 |
| MACD | 0.02 | 0.41 |
| Stochastic Oscillator | 57.83 | 94.35 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.